The Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Drug Des Devel Ther. 2021 Jun 11;15:2495-2505. doi: 10.2147/DDDT.S316636. eCollection 2021.
The aim of this work is to identify the most influential initial clinical studies that fomented important developments in anesthesiology over the past 50 years. Studies fomenting new development can be selected using vastly different approaches and, therefore, might provide diverse outcomes. In the present work, two basic aspects of study assessments - the stage of development (eg, generation of idea, preclinical studies, clinical trials) and the method of selection (eg, committee vote, various types of citation analysis, method of finding the invention disclosure) - were chosen according to the following model. The stage of development: the initial clinical studies demonstrating the basic advantage of an innovation for providing anesthesia. The method: a combination of two factors - the study priority in terms of the time of its publication and the degree of its acknowledgement in the form of citation impact; the time of study publication was regarded as a primary factor, but only if the study's citation count was =/>20. The initial high-impact studies were selected for 16 drug-related topics (ketamine, isoflurane, etomidate, propofol, midazolam in anesthesia, vecuronium, alfentanil, atracurium, sevoflurane, sufentanil, rocuronium, desflurane, ropivacaine, remifentanil, dexmedetomidine in anesthesia, and sugammadex), and 9 technique-related topics (ultrasound-guided peripheral nerve block, capnography in anesthesia, target-controlled intravenous anesthesia, pulse oximetry in anesthesia, total intravenous anesthesia, transesophageal echocardiography in anesthesia, combined spinal-epidural anesthesia, and bispectral index). Twenty-five studies were designated the first high-impact studies (one for each topic); 16 are drug-related and 9 are technique-related. Half of the first high-impact studies had a citation count of =/>100, (range: 100 to 555). The citation count of the other half of high-impact studies did not reach the 100-citation threshold (range: 41 to 97). If a selected first high-impact study had a citation count <100, a next-on-timeline, additional study with citation count =/>100 was also selected; (range: 100 to 344). The present results show that an initial high-impact clinical study on a new development in anesthesiology can be determined and that related citations usually vary from one hundred to five hundred.
本研究旨在确定过去 50 年来在麻醉学领域具有重要发展意义的最具影响力的初始临床研究。选择促进新发展的研究可以采用截然不同的方法，因此可能会得出不同的结果。在本研究中，根据以下模型选择了研究评估的两个基本方面-发展阶段（例如，创意产生，临床前研究，临床试验）和选择方法（例如，委员会投票，各种类型的引文分析，寻找发明披露的方法）。发展阶段：展示创新为提供麻醉带来基本优势的初始临床研究。方法：两个因素的结合-研究的优先顺序，以其发布时间为基础，以及以引文影响形式表示的认可程度；研究发布时间被视为主要因素，但前提是研究的引文计数>=20。选择了 16 个与药物相关的主题（氯胺酮，异氟烷，依托咪酯，异丙酚，麻醉中咪达唑仑，维库溴铵，阿芬太尼，阿曲库铵，七氟醚，舒芬太尼，罗库溴铵，地氟醚，罗哌卡因，瑞芬太尼，麻醉中右美托咪定，和 Sugammadex）和 9 个与技术相关的主题（超声引导外周神经阻滞，麻醉中二氧化碳描记术，靶控静脉麻醉，麻醉中脉搏血氧饱和度，全静脉麻醉，麻醉中经食管超声心动图，联合脊髓-硬膜外麻醉，和双频谱指数）的 25 项初始高影响力研究。指定了 25 项研究为第一项高影响力研究（每个主题一项）；16 项与药物有关，9 项与技术有关。一半的第一项高影响力研究的引文计数>=100（范围：100 至 555）。另一半高影响力研究的引文计数未达到 100 引文阈值（范围：41 至 97）。如果选择的第一项高影响力研究的引文计数<100，则还选择了下一个具有>=100 引文计数的时间线附加研究（范围：100 至 344）。目前的结果表明，可以确定麻醉学新发展的初始高影响力临床研究，并且相关引文通常在一百到五百之间变化。
